Clinical Trials Browser

Terminated × INDUSTRY × ARX788 × Clear all

NCT02512237 2020-06-05

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms